Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPC

Maha Hussain • 30 Sep 2019
ESMO 2019
Genitourinary Cancer Prostate Cancer Abiraterone Enzalutamide Olaparib
PROfound

Maha Hussain, MBChB, FACP, FASCO, of Northwestern University Feinberg School of Medicine, Chicago, IL, presents the results of the phase 3 PROfound study of olaparib vs. enzalutamide or abiraterone for metastatic castration-resistant prostate cancer HRR gene alterations. Next, Ignacio Duran, MD, PhD, Marques de Valdecilla University Hospital, Santander, Spain, discussing the impact of these data.

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals